secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193805-26-000181
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic closes $200M private placement; CEO Vitt to transition; Phase 3 MS data by end-2026
--------------------------------------------------------------------------------

- Closed oversubscribed private placement of up to $400M; $200M gross proceeds received Feb 17, 2026.
- Net proceeds ~$187M expected to fund operations into late 2027, including Phase 3 ENSURE trials and NDA submission mid-2027.
- CEO Daniel Vitt to transition to senior scientific role; search for new CEO with commercial MS expertise underway.
- Simona Skerjanec appointed Interim Chairperson; Thor Nagel (BVF Partners) named to Board.
- Net loss for FY2025 was $97.2M ($0.62/share); cash $15.5M at Dec 31, 2025, plus placement proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000181/0001193805-26-000181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000181/e665186_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer